Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2023 08:00 ET | Source: Clene Inc.

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-upSALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) --...
June 21, 2023 09:20 ET | Source: Clene Inc.

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Investment led by Vivo Capital with participation from SymBiosis, Acuta Capital Partners, AIGH Capital, Serrado Capital LLC, and other new biotech investors, with support from existing insiders $40...
June 16, 2023 08:00 ET | Source: Clene Inc.

Clene Announces Pricing of $40 Million Public Offering

SALT LAKE CITY, June 16, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
June 15, 2023 16:38 ET | Source: Clene Inc.

Clene Announces Launch of Proposed Public Offering

SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
June 15, 2023 16:29 ET | Source: Clene Inc.

Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

CNM-Au8® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04)Clene plans to discuss the totality of the survival and...
June 15, 2023 07:00 ET | Source: Clene Inc.

Clene to Participate in the Maxim Group Virtual Healthcare Conference

SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
May 25, 2023 08:00 ET | Source: Clene Inc.

Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis

SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
May 12, 2023 16:00 ET | Source: Clene Inc.

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical SALT LAKE CITY, May 12, 2023 (GLOBE NEWSWIRE) -- Clene Inc....
April 25, 2023 16:05 ET | Source: Clene Inc.

ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

SALT LAKE CITY, April 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
April 11, 2023 08:00 ET | Source: Clene Inc.

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right